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The Role of Cholesterol Metabolism and Various Steroid
Abnormalities in Autism Spectrum Disorders: A Hypothesis Paper
Christopher Gillberg, Elisabeth Fernell, Eva Kocˇovska, Helen Minnis,
Thomas Bourgeron, Lucy Thompson, and Clare S. Allely
Based on evidence from the relevant research literature, we present a hypothesis that there may be a link between choles-
terol, vitamin D, and steroid hormones which subsequently impacts on the development of at least some of the
“autisms” [Coleman & Gillberg]. Our hypothesis, driven by the peer reviewed literature, posits that there may be links
between cholesterol metabolism, which we will refer to as “steroid metabolism” and findings of steroid abnormalities of
various kinds (cortisol, testosterone, estrogens, progesterone, vitamin D) in autism spectrum disorder (ASD). Further
research investigating these potential links is warranted to further our understanding of the biological mechanisms
underlying ASD.AutismRes 2017, 10: 1022–1044.VC 2017 The Authors Autism Research published byWiley Periodicals,
Inc. on behalf of International Society for Autism Research.
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Introduction
Between 10 and 35% of autism spectrum disorder (ASD)
cases have a known major risk factor or identified
aetiology, meaning that in the majority of individuals
with ASD the exact causes remain unknown [Coleman
& Gillberg, 2012]. Numerous potential factors including
specific genetic, metabolic, infectious, and environmen-
tal factors are being explored [Muhle, Trentacoste, &
Rapin, 2004]. One intriguing hypothesis is that ASD is
a “whole body disorder” [Herbert, 2010], involving
metabolic pathways that are expressed across the whole
body [Schengrund, Ali-Rahmani, & Ramer, 2012].
ASD is diagnosedmuchmore often in boys than in girls
and there has long been speculation and controversy
about the role of “themale brain” and sex hormones (par-
ticularly testosterone) in the pathogenetic chain of
events leading to the clinical disorder and to “autistic
traits” [Bejerot & Eriksson, 2014; Crider, Thakkar,
Ahmed, & Pillai, 2014; Gillberg, 1991; Posserud, Lunder-
vold, & Gillberg, 2006; Wing, 1981]. ASD has also more
recently been linked to stress and stress hormone levels
[Bitsika, Sharpley, Sweeney, & McFarlane, 2014], and to
vitamin D (VitD) insufficiency [Kocˇovska, Fernell, Bill-
stedt, Minnis, & Gillberg, 2012; Kocˇovska et al., 2014; Fer-
nell et al., 2015], perhaps suggesting a more general link
with steroid hormones rather than one that would be
connected specifically with the influence of sex hor-
mones on the developing brain. Finally, a low level of
cholesterol—the “precursor” of all the steroid hormones
with the exception of VitD—has been indirectly linked to
autism in a variety of studies of autism-associated medi-
cal syndromes, ranging from Smith-Lemli-Opitz syn-
drome [Lee & Tierney, 2011] to the Fragile-X-syndrome
[Berry-Kravis et al., 2015]. Research to date provides some
support for the hypothesis that defective cholesterol
homeostasis may be responsible for the onset of ASD in
some children, suggesting that it is worth investigating
whether cholesterol may be a useful biomarker for certain
ASD subtypes [Woods,Wormwood,Wetie, Ryan, & Darie,
2013]. A good overview of steroidogenic enzymes in the
pathway from cholesterol to active steroid hormones can
be found in a paper by Payne and Hales [2004]. It is
important to highlight that VitD is the only steroid
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hormone which is not metabolically synthesized from
cholesterol like all other steroid hormones. The branch-
ing point in the metabolism is 7-dehydrocholesterol
(7DHC) from which both VitD and cholesterol are
formed (see Figure 1 where the double arrows represent
multiple steps within the metabolic process).
Taken together, we believe that these seemingly
divergent lines of evidence warrant further scrutiny.
Based on evidence from the relevant literature we pre-
sent a hypothesis that there is a link between 7DHC,
cholesterol, VitD, and steroid hormones on the one
hand which subsequently impacts on the development
of at least some of the “autisms” [Coleman & Gillberg,
2012] on the other.
Method Section
The present review was too multifaceted, complex, and
conceptual to adopt a systematic PRISMA (PRISMA, Pre-
ferred reporting items for systematic reviews and meta-
analyses) review format [Liberati et al., 2009; Moher,
Liberati, Tetzlaff, & Altman, 2009]. However, we were
strictly inclusive in the searches conducted on relevant
databases (PsycINFO and Pubmed, etc.) and articles sub-
sequently identified as relevant to the present hypothe-
sis paper. We did not selectively include articles
because of favorable results or which supported our
conceptual arguments. All articles which were identified
as relevant were included regardless of findings. Numer-
ous searches were conducted such as: “cholesterol”
AND “autism spectrum disorder*” OR ASD OR asperger*
OR “autism spectrum condition*” OR autism OR autis-
tic. Searches were also conducted on google scholar
using the same search terms used in the database
searches.
Testosterone in Autism Spectrum Disorders
Testosterone is a steroid hormone which is directly
metabolized from cholesterol [Durdiakova et al., 2011].
Several studies have investigated the association
between testosterone and ASD behavioral symptoms
[Krajmer, Janosıkova, Spajdel, & Ostatnıkova, 2010].
These studies have usually been linked to the extreme
male brain theory of ASD [Baron-Cohen, 2002] which
characterizes ASD as an extreme variant of male intelli-
gence [Asperger, 1991; Baron-Cohen, 2002, 2005].
Numerous studies to date indicate that elevated testos-
terone levels may be a risk or associated factor in ASD
[Auyeung & Baron-Cohen, 2013]. However, it is still
unclear whether ASD is generally associated with high
levels of testosterone or if the association is seen only
in a small subset of individuals with ASD. Table 1
shows the studies found which have investigated testos-
terone in ASD.
The “extreme male brain” theory of ASD [Baron-
Cohen, 2002] has generated hypotheses about the role
of elevated fetal sex steroids, such as testosterone, in
the development of ASD. However, it does not take
into account the contribution of other factors such as
sex chromosome effects, or the involvement of other
factors such as 7-dehydrocholesterol, cholesterol, or ste-
roid hormones (including cortisol and VitD) that are
proximal or parallel to testosterone in the biosynthesis
pathways. Individuals with an extra X chromosome,
e.g., boys with Klinefelter syndrome (XXY) and girls
with Trisomy X), are at increased risk for autism symp-
toms [Van Rijn et al., 2014]. Moreover, girls with Tur-
ner syndrome (X0), i.e., with haploinsufficiency of X
chromosome genes, are at increased risk for a number
of neurodevelopmental conditions, generally more
often occurring in males than in females; autism and
ADHD. Moreover, contrary to the “extreme male brain
theory,” Bejerot et al. [2012] posit that rather than
being characterized by masculinization in both genders,
ASD may instead constitute a gender defiant disorder
[Bejerot et al., 2012]. This notion is supported by Strang
et al. [2014] who observed an over-representation of
individuals with ASD referred for gender identity disor-
ders (GID).
It is noteworthy that the neuroimaging literature has
started to address this topic as well and found some
correspondence to, for example, the findings of Bejerot
et al. [2012] reviewed above. Such findings have been
summarized in a recent review by Lai et al. [2017]. For
instance, Lai et al. [2013] adopted whole-brain voxel-
based morphometry in order to investigate the spatial
overlap between normative sex/gender differences in
regional brain volume and autism-related regional brain
volume changes in adult males and females. Findings
revealed that the overall pattern of autism-related brain
changes (in both gray and white matter) in females sig-
nificantly resemble neural masculinization. Conversely,
the autism-related brain changes (in both gray and
white matter) in males was found to be a weaker but
still significant level of resemblance to feminization [Lai
et al., 2013].
However, it remains controversial and not well under-
stood as to whether GID and ASD are associated or,
Figure 1. Figure shows the branching point in the metabolism is
7-dehydrocholesterol (7DHC) from which both VitD and cholesterol
are formed. 7DHC, 7-dehydrocholesterol; VitD, vitamin D.
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Table 1. Studies Which have Investigated Levels of Testosterone in Autism Spectrum Disorder
Testosterone in autism spectrum disorders
Authors Sample Study aims Main findings
Auyeung
et al. [2009]
The Childhood Autism Spectrum Test
(CAST) and the Child Autism
Spectrum Quotient (AQ-Child)
were used to assess ASD traits
and were completed by the
women about their children
(n5 235), ages 6–10 years.
Intelligence Quotient (IQ) was
measured in a subset of children
(n5 74).
To examine the relationship
between ASD traits and FT levels
in amniotic fluid which was
measured during routine
amniocentesis.
There was a positive association
between levels of FT and higher
scores on both the CAST and AQ-
Child, independent of sex which
supports the hypothesis that pre-
natal androgen exposure is asso-
ciated a greater number of ASD
traits in children.
Auyeung
et al. [2010]
129 typically developing toddlers
(age range5 18 and 24 months,
mean age5 19.25 months,
SD5 1.52 months).
To investigate whether fetal
testosterone (FT) is positively
correlated with traits of ASD in
toddlers aged between 18 and 24
months. FT levels were measured
in the amniotic fluid and
compared with autistic traits
which were assessed using the
Quantitative Checklist for Autism
in Toddlers (Q-CHAT).
Study found sex differences in Q-
CHAT scores, with significantly
higher scores found in the boys
(suggesting a greater number of
autistic traits) compared to girls.
Moreover, there was a significant
positive relationship between lev-
els of FT and autistic traits
Baron-Cohen
et al. [2015]
Control group (n5 217) and autism
group (n5 128).
Participants were selected from a
population of singleton births
between 1993 and 1999
(n5 19,677).
To investigate the prediction that
fetal steroidogenic activity is
elevated in ASD.
Specifically, the study measured
concentration levels of D4 sex
steroids (progesterone,
17a-hydroxy-progesterone, andro-
stenedione, and testosterone)
and cortisol with liquid chroma-
tography tandem mass
spectrometry.
Study found that the autism group
had elevated levels of all
hormones on this latent
generalized steroidogenic factor
(Cohen’s d5 0.37, P5 0.0009)
and this elevation was found to
be uniform across ICD-10 diag-
nostic label.
Ingudomnukul
et al. [2007]
A number of groups including:
women with ASD (n 554),
mothers of children with ASD
(n5 74) and mothers of typically
developing children (n5 183)
To examine the rate of
testosterone-related medical con-
ditions in women with ASD and
mothers of children with ASD, as
part of the “broader autism
phenotype.”
Elevated levels of fetal testosterone
(FT) show a positive correlation
with a variety of ASD traits and
an inverse correlation with social
development and empathy.
Significantly more women with ASD,
when compared to controls, were
found to have conditions
associated with elevated levels of
androgen including: hirsutism;
bisexuality or asexuality; irregular
menstrual cycle; dysmenorrhea;
polycystic ovary syndrome; severe
acne; epilepsy; “tomboyism” and
a family history of ovarian,
uterine, and prostate cancers,
tumours, or growths.
Additionally, compared to
mothers of typically developing
children, there were significantly
more reports of severe acne,
breast and uterine cancers,
tumors, or growths, and family
history of ovarian and uterine
cancers, tumours, or growths in
the mothers of children with ASD.
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alternatively, if the behaviors found in individuals with
GID are atypical manifestations of restricted, repetitive,
and stereotypical behaviors and interests. Prevalence of
GIDs among the general population has been suggested
to be nearly identical in males and females [Landen,
Wa˚linder, & Lundstr€om, 1996]. Interestingly, de Vries,
Noens, Cohen-Kettenis, van Berckelaer-Onnes, and Dore-
leijers [2010] found that more males than females with
ASD experienced GID or GD (gender dysphoria) [de Vries
et al., 2010] which is inconsistent with the hypothesis
that prenatal androgen exposure may increase male-
typical characteristics in individuals with ASD—the
Table 1. Continued
Testosterone in autism spectrum disorders
Authors Sample Study aims Main findings
Knickmeyer,
Baron-Cohen,
Fane et al. [2006]
Sixty individuals with congenital
adrenal hyperplasia (CAH) (34
female, 26 male) and 49
unaffected relatives (24 female,
25 male)
To investigate the hypothesis that
autistic traits are increased
following prenatal exposure to
abnormally high levels of
testosterone caused by CAH.
Study found a greater number of
ASD traits in girls with
abnormally high fetal
testosterone (FT) levels as a
result of CAH compared to their
unaffected sisters. These findings
have led to the androgen theory
of ASD which proposes that
elevated levels of FT are a
contributory factor in ASD
occurrence.
Kosidou
et al. [2016]
23,748 ASD cases and 208,796
controls.
Children aged 4–17 who were born
in Sweden from 1984 to 2007.
A population-based study to investi-
gate the relationship between
maternal diagnosis of polycystic
ovary syndrome (PCOS) and the
risk of ASD in the offspring.
Study found that maternal PCOS
increased the odds of ASD in the
offspring by 59%, following
adjustment for confounding
factors (odds ratio [OR] 1.59,
95% confidence interval [CI]
1.34–1.88). Findings also
revealed that the odds of
offspring ASD were even greater
in mothers with both PCOS and
obesity, a condition common to
PCOS that is related to more
severe hyperandrogenemia (OR
2.13, 95% CI 1.46–3.10). There
were no differences in risk
estimates between sexes.
Takagishi
et al. [2010]
92 healthy, Japanese adults (45
males and 47 females, mean
age5 47.9, SD5 12.4; age
range5 21–68).
To investigate whether the
relationship between testosterone
levels and ASD traits found in
numerous studies on young
children is also supported by data
on adults. Indeed, one study
examined the relationship
between salivary testosterone
levels and ASD traits [using the
Japanese version of Autism
Spectrum Quotient (AQ)] in 92
healthy, Japanese adults.
When males and females were
combined into one group, there
was a positive correlation
between T and AQ. However, this
correlation did not occur when
correlation analysis by sex was
performed. No sex difference in
the score of the subscale of
attention switching were found
in relation to T.
Whitehouse
et al. [2012]
184 males (M5 20.10 years; SD5
0.65 years) and 190 females
(M5 19.92 years; SD5 0.68
years). Also, umbilical cord blood
was collected from 707 children
To investigate, for the first time,
the prospective relationship
between umbilical cord
testosterone concentrations and
characteristics of autism.
Findings suggest that testosterone
concentrations from umbilical
cord blood are unrelated to
autistic-like traits in the general
population.
Findings do not exclude an
association between testosterone
exposure in early intrauterine life
and ASD.
CAST, the childhood autism spectrum test; AQ-Child, child autism spectrum quotient; IQ, intelligence quotient; ASD, autism spectrum disorders;
FT, fetal testosterone; M, mean; SD, standard deviation; Q-CHAT, quantitative checklist for autism in toddlers; CAH, congenital adrenal hyperplasia;
PCOS, polycystic ovary syndrome; AQ, autism spectrum quotient; T, testosterone.
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extreme male brain theory [Baron-Cohen, Knickmeyer, &
Belmonte, 2005]. (In May 2013, the DSM-5 [American
Psychiatric Association, 2013] outlined a new diagnostic
criteria for Gender Dysphoria (GD) which was formerly
Gender Identity Disorder [GID, DSM-IV-TR]). According
to the extreme male brain theory, females with ASD
should be more susceptible to developing GD and it also
fails to explain why males with ASD would experience
GID [De Vries et al., 2010; Kirkovski, Enticott, & Fitzger-
ald, 2013]. Other factors, including environmental ones
(e.g., certain pesticides exposure, long term exposure to
toxic chemicals) may increase risk for ASD, which high-
lights the need for further research using multiple per-
spectives [Wormwood, Dupree, Darie, & Woods, 2014].
Lastly, research needs to explore the possibility that low
levels of cholesterol could be linked to high testosterone.
Low levels of cholesterol would definitely be linked to
low levels of estrogens and cortisol.
There have been two recent studies which have
shown the risk roles of prenatal steroids (including
androgens) for childhood ASD. Baron-Cohen et al.
[2015], used the Danish Historic Birth Cohort and
Danish Psychiatric Central Register and identified all
amniotic fluid samples of males who were born
between the years 1993–1999 and who also had later
received ICD-10 diagnoses of autism, Asperger Syn-
drome, or PDD-NOS (n5128). This group was com-
pared to a matched typically developing control group.
Baron-Cohen et al. [2015] tested the concentration
levels of D4 pathway sex steroids (progesterone, 17a-
hydroxy-progesterone, androstenedione, and testoster-
one) and cortisol. The findings revealed that there were
elevated levels across all hormones in the ASD group.
Interestingly, this elevation of hormones was uniform
across ICD-10 diagnostic subgroups. This study is the
first direct support for the existence of elevated fetal
steroidogenic activity in ASD [Baron-Cohen et al.,
2015]. In their other study, Kosidou et al. [2016] inves-
tigated whether maternal polycystic ovary syndrome
(PCOS), a condition associated with excess androgens,
would increase the risk of the development of ASD in
the children of mothers with this syndrome. They car-
ried out a matched case-control study nested within the
total population of Sweden (children aged 4–17 who
were born in Sweden between the years of 1984 and
2007). The study comprised of 23,748 ASD cases and
208,796 controls. The controls were matched by birth
month and year, sex, and region of birth. Findings
from the study revealed that maternal PCOS increased
the odds of ASD in the offspring by 59%. The odds of
offspring ASD were further increased among mothers
with both PCOS and obesity, a condition common to
PCOS that is related to more severe hyperandrogenemia.
There were no significant differences between males and
females regarding the risk associated with PCOS. In sum,
maternal diagnosis of PCOS increased the risk of the
offspring of these mothers developing ASD [Kosidou
et al., 2016]. This is consistent with the findings from
the same group of researchers that maternal PCOS can
result in an increased risk for neurodevelopmental disor-
ders such as attention-deficit/hyperactivity disorder
(ADHD) [Kosidou et al., 2016].
Given that the “extreme male brain” theory of ASD
[Baron-Cohen, 2002] has investigated the role of elevat-
ed fetal sex steroids, such as testosterone, in the devel-
opment of ASD, it would be of clinical importance to
take this investigation even further and explore the
possible contribution of other factors such as sex chro-
mosome effects, or the involvement of other factors
such as cholesterol or steroid hormones (including cor-
tisol and VitD) that are proximal or parallel to testoster-
one in the biosynthesis pathways. These potential
factors will be explored in the next sections of this
hypothesis paper.
Estrogens in Autism Spectrum Disorder
One posited explanation for the “extreme male brain
theory” is that there may have been an insufficient sup-
ply of estrogens from the mother during embryonic
development, coupled with the fact that females are
exposed in utero and postnatally to higher levels of estro-
gen and also to oxytocin, and to lower levels of andro-
gens [Pfaff, Rapin, & Goldman, 2011]. This theory of
estrogens deficiency as a feature of ASD is consistent with
the clinical observation that ASD is associated with
reduced cortical thickness in bones [Hediger et al., 2008].
However, this theory is inconsistent with the endocrino-
logical processes which take place. Specifically, it is impor-
tant to separate the activating effects of testosterone (i.e.,
the effects exerted by the circulating hormone in adults),
which are “acute,” and early organizational effects which
are exerted during development, and which are perma-
nent (i.e., remaining also in the absence of the hormone).
The former are exerted partly by androgen receptors and
may well be influenced by the testosterone versus estro-
gens ratio (though some of the testosterone effects are in
fact mediated by estrogen receptors after the conversion
of testosterone to estradiol). The latter, on the other
hand, are more or less solely exerted by testosterone act-
ing via estrogen receptors (in males but not in females
since testosterone but not estrogens may enter the rele-
vant cells) [Angelopoulou, Lavranos, & Manolakou,
2006]. Given these effects, estrogens may not exert much
of an opposing influence. Rather, there have been reports
suggesting that administration of exogenous estrogens to
pregnant women, leading to estrogen excess, may in fact
cause a masculinization of the fetus (though this has also
been questioned) [Ehrhardt et al., 1985]. Strifert [2014]
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has recently hypothesized that estrogens and progester-
one, which are used in oral contraceptives, modify the
condition of the oocyte producing a potent risk factor for
ASD [Strifert, 2014]. See Table 2 for studies which have
investigated estrogen levels in ASD.
Cortisol in Autism Spectrum Disorders
The primary stress hormone in humans is cortisol
which is released from the adrenal cortices after
limbic-hypothalamic-pituitary-adrenocortical (HPA)
axis activation in response to physiological and/or psy-
chological stress [Hennessey & Levine, 1979; Herman
& Cullinan, 1997]. Cortisol exhibits a normal circadian
rhythm, increasing sharply and peaking in early morn-
ing (the cortisol awakening response [CAR]) typically
around 30 min after waking and the levels of cortisol
then decline throughout the remainder of the day. In
addition, cortisol can be activated by threat which is
real or simply perceived by the individual [Corbett &
Simon, 2013]. It has been understood for some time
that individuals with ASD are impaired in their ability
to adapt to novel and rapidly changing situations
[Kanner, 1943]. This has prompted research to study
the stability of the HPA axis which has highlighted
heightened reactivity in response to different stressors
[Corbett, Mendoza, Abdullah, Wegelin, & Levine,
2006; Corbett, Schupp, & Lanni, 2012; Richdale & Pri-
or, 1992; Tordjman et al., 1997]. Cortisol therefore has
a role in both circadian rhythms (e.g., sleep) and a
stress responsivity, both of which can be impaired in
ASD.
Studies to date investigating the diurnal regulation of
cortisol in individuals with ASD compared to typically
developing controls [e.g., Corbett et al., 2006; Corbett,
Mendoza, Wegelin, Carmean, & Levine, 2008; Richdale
& Prior, 1992] have produced inconsistent findings. The
lack of consistent findings across the studies investigat-
ing the CAR in individuals with ASD compared to those
without a diagnosis of ASD [e.g., Brosnan, Turner-Cobb,
Munro-Naan, & Jessop, 2009 vs. Zinke, Fries, Kliegel,
Kirschbaum, & Dettenborn, 2010] may be attributable
to differences across many factors including: age/stage
of developmental (adolescence vs. childhood), the diag-
nostic criteria used, and diagnostic distinctions (e.g.,
Asperger syndrome vs. High Functioning Autism [HFA]),
the setting from which the sample was derived (institu-
tional living vs. home) or medication status of the indi-
viduals (off vs. on medication) [Corbett & Schupp,
2014]. See Table 3 for studies which have investigated
cortisol in ASD.
Vitamin D in Autism Spectrum Disorders
Vitamin D” (VitD) is in fact a hormone rather than a
vitamin, comprising a group of several fat-soluble steroid
molecules which are transformed through metabolic cas-
cade into its active form (e.g., the multifunctional
Table 2. Studies Which have Investigated Levels of Estrogen in Autism Spectrum Disorder
Estrogen and autism spectrum disorder
Authors Sample Study aims Main findings
Chakrabarti
et al. [2009]
Individuals (n5 349).
143 males and 206 females, mean
age5 22.5 years, SD5 2.6 years).
To investigate whether genes
related to sex steroids, neural
growth, and social–emotional
behavior are associated with
autistic traits, empathy, and
Asperger syndrome.
This study found a significant association
of the ERb gene with scores on the
Autism Spectrum Quotient and the
Empathy Quotient in individuals with
ASD.
Crider
et al. [2014]
Samples of postmortem middle
frontal gyrus tissues from 13
individuals who had received a
diagnosis of ASD and 13 controls.
To investigate estrogen receptor
beta (ERb), aromatase (CYP19A1),
and ER co-activators in the
middle frontal gyrus in
individuals with ASD compared to
individuals without ASD.
This study is the first to provide evidence
of the dysregulation of ERb and co-
factors in the brain of individuals with
ASD. Molecular alterations within the ER
signalling pathway may be one factor
underlying the sex difference in ASD.
Gene expression was ascertained by qRT-
PCR. A 35% decrease in ERb mRNA
expression in the middle frontal gyrus of
ASD subjects was found based on the
gene expression analysis. Furthermore, a
reduction of 38% in aromatase
(CYP19A1) mRNA expression was found
in the samples derived from the ASD
participants.
SD, standard deviation; M, mean; ASD, autism spectrum disorders; ERb, estrogen receptor beta; CYP19A1, aromatase.
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Table 3. Studies Which have Investigated Cortisol in Autism Spectrum Disorder
Cortisol in autism spectrum disorders
Authors Sample Study aims Main findings
Brosnan
et al. [2009]
All male and aged between 11 and
16 years and medication free
To investigate cortisol
awakening response (CAR)
magnitude over 2 days in 20
adolescent males with Asperger
Syndrome (AS) from an
institutional setting compared to
18 typically developing (TD)
youth from the community.
While a significant CAR was
evidenced in the TD control
group (28%), this was not the
case for those with AS (where
CAR was only seen in 5%). In
both groups, there was evidence
of a normal diurnal decrease in
cortisol.
Corbett
et al. [2008]
Circadian rhythms of cortisol were
estimated in 22 children with and
22 children without autism via
analysis of salivary samples
collected in the morning,
afternoon, and evening over 6
separate days.
The 44 subjects were predominantly
male children between 6.5 years
and 12 years of age (mean age
9.08 y), 22 of whom were
diagnosed with autism (1 female
child) according to a strict
diagnosis and 22 of whom were
neurotypical children (3 female
children).
To replicate and extend their
previous findings showing
variable circadian rhythm and
significant elevations in cortisol
following exposure to a novel
stimulus (mock magnetic
resonance imaging [MRI]).
In children with ASD, a flattening
of the diurnal slope over time
was found in which morning
cortisol levels are diminished and
evening cortisol levels are
elevated.
Corbett
et al. [2009]
44 predominantly male children
between 6-years and 12-years of
age (mean age 9.08 years), 22
diagnosed with autism (1 female)
and 22 neurotypical children (3
females).
To investigate plausible explanatory
factors which may contribute to
the variability in limbic
hypothalamic pituitary
adrenocortical (LHPA) regulation
and responsivity in children with
autism.
Diminishing morning cortisol was
associated with sensory
sensitivity and elevated evening
cortisol levels were associated
with poor adaptation to changes.
Corbett and
Schupp [2014]
94 prepubertal male children
between eight and 12 years with
ASD (n5 46) and typical
development (TD, n5 48)
Over three diurnal cycles, salivary
samples were collected involving
two morning samples: M1:
Immediately upon Waking and
M2: 30-min Post Waking
(M22M15 cortisol awakening
response (CAR).
Findings revealed no significant
differences, over the three days
of testing, on the CAR between
the groups based on magnitude,
variability or the sequence.
Whether the child or adult
criterion was used, there were
still no significant differences in
the proportion of children
exhibiting a CAR across the
groups. So in sum, although
there are differences in the
regulation and responsivity of
cortisol between the individuals
with ASD and those without,
there are no differences in the
CAR between the groups.
Lydon et al. [2015] 61 children and adolescents with a
diagnosis of ASD (age range from
3 to 18 years).
To investigate the relationship
between a parent-reported mea-
sure of stress, a physiological
measure of stress (diurnal salivary
cortisol) and a variety of topogra-
phies of challenging behavior in
61 children and adolescents with
a diagnosis of ASD.
The findings indicated that there
are comparable levels of stress
present among children with ASD
and their typically developing
peers. However, for a subset of
the children with ASD,
stereotyped behavior may be an
indicator of elevated levels of
cortisol.
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hormone Calcitriol). VitD3 (cholecalciferol) is primarily
involved in calcium physiology and bone metabolism
[Christodoulou, Goula, Ververidis, & Drosos, 2013], but
also in modulating immune function, cell proliferation
and apoptosis, brain development and function, and has
also been found to have neuroprotective properties
[Holick, 2007].
Sunlight exposure is known to impact on VitD syn-
thesis and has also been explored in relation to ASD.
The notion of a potential association between VitD and
ASD was derived from a number of observational stud-
ies conducted in Northern Europe and North America
which all observed higher rates of ASD in dark-skinned
children [Barnevik-Olsson, Gillberg, & Fernell 2008;
Table 3. Continued
Cortisol in autism spectrum disorders
Authors Sample Study aims Main findings
Tordjman
et al. [2014]
55 low-functioning children and
adolescents with ASD (11.36 4.1
years-old) and 32 typically
developing controls (11.76 4.9
years-old) who were age-, sex-,
and puberty state-matched.
To investigate cortisol levels in 55
low-functioning children and
adolescents with ASD (11.36 4.1
years-old) and 32 typically
developing controls (11.76 4.9
years-old) who were age-, sex-,
and puberty state-matched. The
Autism Diagnostic Observation
Schedule (ADOS) was used to
conduct behavioral assessment
and salivary samples to measure
levels of cortisol were collected
over 24 hr.
Significantly higher levels of
salivary cortisol were exhibited at
all time-points in the individuals
with ASD. Compared to the
typically developing control
group, individuals with ASD also
exhibited greater variances of
salivary and urinary cortisol. A
significant association was also
found between salivary cortisol
levels and impairments in social
interaction and verbal language.
Similar levels of overnight urinary
cortisol excretion were found
between the two groups which
suggests that there are not
abnormalities in the functioning
of the basal HPA axis in
individuals with low-functioning
ASD.
Yang
et al. [2015]
ASD (n5 35), mean age 10.63
(SD5 2.64) (28 males and 7
females) and controls (n5 32),
mean age 11.19 (SD5 2.61) (25
males and 7 females).
To investigate diurnal variation of
cortisol (cortisol VAR),
interleukin-6 (IL-6) and tumor
necrosis factor-alpha (TNF-a) in
order to determine whether they
may be clinically useful bio-
markers for ASD.
Findings revealed that, compared to
the healthy controls, individuals
with ASD exhibited a lower level
of cortisol VAR, higher level of
IL-6 and TNF-a. There was a
significant correlation between
levels of cortisol VAR, IL-6, and
TNF-a and severity of ASD
symptoms as measured using
CARS. Analysis showed that
cortisol VAR, IL-6, and TNF-a are
possible biomarkers for ASD and
that when cortisol VAR, IL-6, and
TNF-a are combined, they
demonstrate the highest
sensitivity and specificity for
ASD.
Zinke
et al. [2010]
15 children with high-functioning
autism (HFA) and 25 TD children
(all aged between 6 and 12 years
of age). Seven of the children
with HFA had comorbid
conditions and six were on
medication.
To investigate the CAR over two
days in 15 children with
high-functioning autism (HFA)
and 25 TD children
Frequency of the CAR was similar
between children with ASD and
those without (80 vs. 88%,
respectively). No significant
differences based on the adult
criterion [Wust et al., 2000] were
exhibited in children with ASD
compared to those without a
diagnosis of ASD (73 vs. 84%,
respectively).
SD, standard deviation; M, mean; CAR, cortisol awakening response; AS, Asperger’s syndrome; TD, typically developing; VD, vitamin D; MRI, mag-
netic resonance imaging; ASD, autism spectrum disorders; LHPA, limbic hypothalamic pituitary adrenocortical; Cortisol VAR, variation of cortisol; IL-
6, interleukin-6; TNF-a, tumor necrosis factor-alpha; HFA, high-functioning autism.
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Cannell, 2008; Eyles, 2010; Gillberg, Schaumann, &
Gillberg, 1995; Goodman & Richards, 1995; Keen, Reid,
& Arnone, 2010]. In these Northern areas, there is less
intensive solar radiation throughout the year. Individu-
als who are dark-skinned require greater levels of UV
ray exposure in order to synthesize VitD [Clemens,
Adams, Henderson, & Holick, 1982], leading to an
increased risk for VitD deficiency. A higher prevalence
of ASD at higher latitudes was also found [Grant &
Soles, 2009], and the rate of ASD in these higher lati-
tudes was even higher again in dark-skinned offspring
born to immigrant mothers, particularly the mothers
who came from East Africa to Northern Europe [Deal-
berto, 2011]. More recently, an ecological study carried
out by Grant and Cannell [2013] in the United States
investigated the association between sun exposure and
rates of ASD. A negative correlation between ASD preva-
lence and solar UV-B doses—measured using Total
Ozone Mapping Spectrometer [Leffell & Brash, 1996]—
was found. Cannell and Grant have also suggested that
insufficient VitD is a factor in inducing ASD and
Cannell has advocated the use of oral VitD supplemen-
tation to reduce the risk of ASD [Cannell, 2008, 2013;
Cannell & Grant, 2012; Grant & Cannell, 2013]. VitD
supplementation should be given both in pregnancy
and possibly also during the childs early life.
One recent study highlighted a link between VitD
and serotonin production [Patrick & Ames, 2014]. It
was found that the VitD hormone activates the gene
which produces the enzyme tryptophan hydroxylase 2
(TPH2) that converts the essential amino acid trypto-
phan to serotonin in the brain. This indicates that ade-
quate levels of VitD may be needed to produce
serotonin in the brain where it shapes the structure and
wiring of the brain, acts as a neurotransmitter, and
affects social behavior. Evidence was also found that
the gene that makes the enzyme tryptophan hydroxy-
lase 1 (TPH1) is inhibited by VitD hormone, which sub-
sequently stops the production of serotonin in the gut
and other tissues, where, when found in excess, it pro-
motes inflammation [Patrick & Ames, 2014].
In summary, VitD deficiency does appear to exist in
at least a subgroup of individuals with ASD but whether
the VitD deficiency in itself contributes to ASD is
unclear. A review of the literature on VitD deficiency
and ASD emphasized the need for the recognition of
and for further research into the potential crucial
involvement of VitD in ASD [Kocˇovska et al., 2012]. See
Table 4 for studies which have investigated levels of
VitD in ASD. VitD is the only steroid hormone that is
not metabolically synthesized directly from cholesterol,
but from its “predecessor” 7-hydrocholesterol (7DHC).
We have found no empirical evidence of high testoster-
one levels in low vitamin D production from 7DHC.
However, if 7DHC is not metabolized into VitD (such as
in the absence of sunlight exposure or if the enzymatic
activity of the final steps of the calcitriol synthesis is
impaired, or if its degradation is enhanced), then more
cholesterol would be available for production of higher
levels of testosterone and other steroid hormones. Also,
low cholesterol levels could result from high turnover
of 7DHC to VitD, from primarily low levels of meva-
lonic acid or from the impaired enzymatic activity
mentioned above.
The Cholesterol-Steroid Hormone Pathways
and Autism Spectrum Disorder
In the previous section, we reviewed studies which
linked some of the steroid hormones, specifically VitD,
with cholesterol. We also found studies linking other
steroid hormones, namely testosterone; estrogens and
cortisol with ASD. Therefore, it is possible that there
may exist a cholesterol-steroid hormone pathway
underlying the development of ASD in some individu-
als. An increasing number of studies are finding altera-
tions in cholesterol metabolism in some individuals
with ASDs [Schengrund et al., 2012]. A number of heri-
table disorders have been found to be associated with
ASD including: fragile X syndrome [e.g., Brown et al.,
1982], phenylketonuria [e.g., Baieli, Pavone, Meli, Fiu-
mara, & Coleman, 2003; Kumar, 2014; Saad, Hammad,
Abdel-rahman, & Sobhy, 2013], tuberous sclerosis
[Asano et al., 2001; Bolton & Griffiths, 1997; Gillberg,
Gillberg, & Ahlsen, 1994; Smalley, 1998; Wiznitzer,
2004], and Smith-Lemli-Opitz syndrome (SLOS) [Sikora,
Pettit-Kekel, Penfield, Merkens, & Steiner, 2006; Tier-
ney, Nwokoro, & Kelley, 2000].
SLOS is becoming increasingly recognized as a clini-
cally useful model for understanding the genetic mech-
anisms underlying ASD [Aneja & Tierney, 2008; Diaz-
Stransky & Tierney, 2014]. SLOS is an autosomal reces-
sive disorder of cholesterol metabolism caused by muta-
tions of the 7-dehydrocholesterol (7DHC) reductase
gene (DHCR7) [Tint et al., 1994], found on chromo-
some 11q12–13 [Wassif et al., 1998]. In individuals
with SLOS (prevalence 1/20,000) insufficient levels of
cholesterol are produced in the body and 7DHC accu-
mulates [Aneja & Tierney, 2008; Porter, 2008]. The
behavioral phenotype of SLOS exhibits features which
overlap with those found in individuals with ASD such
as impaired language and social abilities as well as ste-
reotyped and repetitive behaviors [Tierney et al., 2001].
Overall, there appears to be good evidence to suggest
that ASD is present in individuals with SLOS. There is
evidence of SLOS being present in individuals identified
as having ASD [Bukelis, Porter, Zimmerman, & Tierney,
2007]. Numerous studies have investigated the presence
of cholesterol abnormalities in individuals with ASD.
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Table 4. Studies Investigating Levels of Vitamin D in Autism Spectrum Disorder
Vitamin D in autism spectrum disorders
Authors Sample Study aims Main findings
Azzam
et al. [2015]
A prospective case–control
6-month study was carried
out including 21 children
with ASD who were ran-
domly assigned to one of
two groups.
The patients in group I were
administered a daily oral dose of
vitamin D3 and the patients in
group II were not administered
any supplements. Symptoms of
ASD were measured both
presupplement and
postsupplement using the
Childhood Autism Rating Scale,
social IQ, and Autism Treatment
Evaluation Checklist.
Both groups exhibited improved ASD
symptoms but the improvement found in
the supplemented group did not differ
significantly from that of the
nonsupplemented group.
Azzam et al. [2015] have administered 2,000 IU
per day for 6 months (n5 21) and reported no
changes on CARS scores. This treatment
resulted only in a moderate improvement in
children with ASD from their
presupplementation average levels of 47
nmol/L to their post supplementation average
levels of 70 nmol/L.
Bener, Khattab,
and Al-Dabbagh
[2014]
254 children with ASD (mean
age 5.51, SD5 1.58) and
254 healthy control
children (mean age, 5.76
SD5 1.56)
To investigate the association
between VitD and ASD, and the
difference in level of VitD in
children with ASD and children
without ASD.
VitD deficiency was greater in children with
ASD when compared to healthy children and
providing infants with VD supplements may
be a more effective intervention for
lowering the risk of ASD.
Compared to the control children, a lower
level (mean value) of VitD in the children
with ASD was found. Of total 254 children
with ASD, 14.2% had severe VitD deficiency,
43.7% were moderately insufficient, 28.3%
were mildly insufficient, and sufficient
levels of VD was found in only 13.8% of the
children with ASD. Of the 254 of control
children 8.3% were found to have a severe
VitD deficiency, 37% were moderately
insufficient, 37.4% were mildly insufficient,
and sufficient levels were found in only
17.3%. Serum level of VitD was also
significantly different between the children
with ASD and control children.
De Souza-Tostes,
Polonini, Gattaz,
Raposo, and
Baptista [2012]
24 children (18 male and 6
female, mean
age5 7.46 2.7 years)
diagnosed with ASD.
To confirm previous evidence
suggesting an association
between autism and low VitD
serum levels.
Findings showed that the serum levels of 25-
OHD were lower in children with autism
compared to typically developing
participants.
Fernell et al. [2015] 47 Gothenburg sibling pairs
with mixed ethnicities and
11 Stockholm sibling pairs
with Somali background.
The aim of the present study was to
address the emerging
hypothesis that low levels of VitD
at birth increase the risk for ASD.
First study whose findings excluded
ASD-related lifestyle mechanisms
as a possible theory for deficient
25(OH)D levels given that sam-
ples were taken shortly after
birth.
Collapsed group of children with ASD had
significantly lower VitD levels compared
with their siblings. VitD deficiency was
found in both the children with ASD with
African/Middle East background and their
non-ASD siblings. These findings are consis-
tent with the hypothesis that during preg-
nancy, developmental VD deficiency may be
one of the factors involved in increasing
the risk of ASD in the child.
Gong et al.
[2014]
48 confirmed ASD cases and
48 age-matched and
sex-matched controls.
Mean age (%) for ASD
group5 40 (83.3)
Mean age (%) for control
group5 40 (83.3)
To investigate the serum 25(OH) D
levels in Chinese children with
ASD.
The mean serum 25(OH) D levels were
significantly lower in children with ASD
compared to the children without ASD.
There was a significant negative
relationship between circulating serum
25(OH) D levels and the severity of autism
evaluated according to Childhood Autism
Rating Scale scores, after adjustment for
the possible covariates. Lower 25(OH) D
levels may be independently associated
with severity of ASD among Chinese
patients, and lower serum 25(OH) D levels
could be considered as an independent risk
factor for ASD.
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Table 4. Continued
Vitamin D in autism spectrum disorders
Authors Sample Study aims Main findings
Humble et al.
[2010]
Mean age 36.5 of group of
individuals with ASD
(n5 10). 40% were
females.
To investigate 25(OH)VitD levels of
individuals with ASD (including
other psychiatric conditions).
Patients with ADHD had unexpectedly low
intact parathyroid hormone (iPTH) levels.
Middle East, South-East Asian, or African
ethnic origin, being a young male and hav-
ing a diagnosis of ASD or schizophrenia pre-
dicted low 25-OHD levels.
Jia et al. [2015] Case study of a 32-month-
old boy with ASD and
vitamin D3 deficiency.
Investigating Vitamin D/D3
supplementation in a case of
deficiency.
Following vitamin D3 supplementation, the
boy’s core ASD symptoms were significantly
reduced indicating that vitamin D3 may be
one of the factors contributing to the
etiology of ASD.
Kocˇovska et al.
[2014]
The case group consisting of
a total population cohort
of 40 individuals with ASD
(aged 15–24 years) were
compared to 62 typically-
developing siblings and
their 77 parents and also
40 healthy age and gender
matched comparisons.
To investigate, using a cross-
sectional population-based study
conducted in the Faroe Islands,
levels of 25-Hydroxyvitamin D3
(25(OH)D3) in a case group of a
total population cohort of 40
individuals with ASD.
The ASD group were found to have a
significantly lower 25(OH)D3 when
compared to the 25(OH)D3 level in their 62
typically developing siblings and their 77
parents, as well as being significantly lower
than 40 healthy age and gender matched
comparison cases. A trend also revealed
that males had lower 25(OH)D3 levels
compared to females. Interestingly, there
was no association between 25(OH)D3 and
age, month/season of birth, IQ, various
subcategories of ASD and, most
interestingly, Autism Diagnostic
Observation Schedule scores.
Meguid et al.
[2010]
The mean age6 standard
deviation (SD) of the
children with ASD was
5.36 2.8 years. Controls
included 42 age-matched
randomly selected healthy
children of the same socio-
economic status (mean
age6 SD, 6.16 1.8 years).
To measure the potential role of
VitD in ASD through serum level
assessment.
Findings showed that the children with ASD
exhibited a significantly lower 25(OH)D and
1,25(OH)2D compared to controls. The
children with ASD also exhibited
significantly lower calcium serum values
compared to the controls. A significant
positive correlation was found between
25(OH)D and calcium within the children
with ASD.
Molloy, Kalkwarf,
Manning-
Courtney,
Mills, and
Hediger [2010]
Three groups of Caucasian
males age 4–8 years old:
(1) ASD and an
unrestricted diet (n5 40),
(2) ASD and a casein-free
diet (n5 9), and (3) unaf-
fected controls (n5 40).
To examine the plasma 25(OH)D
concentration levels across three
groups (1) ASD and an
unrestricted diet, (2) ASD and a
casein-free diet, and (3) unaf-
fected controls.
A total of 54 (61%) of the children in the
entire cohort had a plasma 25(OH)D
concentration of less than 20 ng/mL
Children with and without ASD have low
plasma concentrations of 25(OH)D.
There were no significant group differences.
25(OH)D concentrations do not differ
between children with ASD and typically
developing controls.
Mostafa and
Al-Ayadhi
[2012]
50 children with ASD, aged
between 5 and 12 years,
and 30 healthy-matched
children.
This is the first study to
investigate the relationship
between serum levels of 25-
hydroxy VitD and anti-myelin-
associated glycoprotein
(anti-MAG) auto-antibodies in
children with ASD.
Children with ASD had significantly lower
serum levels of 25-hydroxy VitD than
healthy children with 40 and 48% being
VitD deficient and insufficient, respectively.
Serum 25-hydroxy VitD had
significant negative correlations with Child-
hood Autism Rating Scale. Increased levels
of serum anti-MAG
auto-antibodies were found in 70% of chil-
dren with ASD.
Saad et al.
[2015]
122 children with ASD (3–9
years of age, mean
age5 5.09).
100 control cases (3–9 years
of ages, mean
age5 4.88).
To investigate individuals with ASD
VitD status compared to controls
and the relationship between
VitD deficiency and the severity
of ASD. Also, to conduct an open
trial of VitD supplementation in
children with ASD.
57% of the patients had VitD deficiency, and
30% had VitD insufficiency. Mean 25-OHD
levels in patients with severe ASD were sig-
nificantly lower compared to those with
mild/moderate ASD. Serum 25-OHD levels
had significant negative correlations with
Childhood Autism Rating Scale (CARS)
scores. Of the ASD group, 106 patients with
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Table 4. Continued
Vitamin D in autism spectrum disorders
Authors Sample Study aims Main findings
low-serum 25-OHD levels (<30 ng/mL) par-
ticipated in the open label trial. They
received VitD3 (300 IU/kg/day not to exceed
5,000 IU/day) for 3 months. 83 participants
completed 3 months of daily VitD treatment.
Collectively, 80.72% (67/83) of participants
who received VitD3 treatment had
significantly improved outcome, mainly in
the sections of the CARS and
aberrant behavior checklist subscales that
measure behavior, stereotypy, eye contact,
and attention span.
Schmidt et al. [2015] ASD (n5 474) and typical
development (TD,
n5 281).
Age range for both
groups5 24–60 months.
To investigate the associations (if
any) between ASD and common,
functional polymorphisms in VitD
pathways.
Preliminary evidence that paternal and child
VitD metabolism may contribute to some
degree in the etiology of ASD.
Paternal VDR TaqI homozygous variant
genotype was significantly associated with
ASD in case–control analysis and there was
a trend toward increased risk associated
with VDR BsmI. Further analyses identified
parental imprinting, with greater effects of
paternally derived VDR alleles.
Ucuz et al. [2014] 64 toddlers with
developmental delay.
In the initial assessment, a
psychiatric examination and
developmental tests were carried
out and VitD was measured.
Individuals found to have low VitD levels in
the initial assessment received
supplementary treatment. Six months later,
the same measures were repeated which
revealed a significant improvement in ASD
symptoms and development scores for the
group who received VitD supplementation.
Study found evidence which supports the
importance of measuring VitD levels and
supplementing them if they are low in
individuals with ASD.
Utur and Gurkan [2014] 54 young children, aged 3–
8 years, with ASD and 54
age and gender matched
normal controls.
First preliminary evidence that
paternal and child vitamin D
metabolism could play a role in
the etiology of ASD.
To investigate the serum levels of
VitD, calcium (Ca), phosphorus
(P), alkaline phosphatase (ALP),
and folate in children with ASD
compared to children without
ASD.
Paternal homozygous variant genotypes for
the TaqI and BsmI polymorphisms on the
VDR gene, and CYP27B1 rs4646536 were
associated with increased risk for ASD. The
CYP2R1 enzyme catalyses the
transformation of vitamin D3 to 25(OH)D3,
the main circulating VitD metabolite. The
CYP2R1 GG genotype associated with higher
risk for ASD in this study was also
associated with lower circulating 25(OH)D3
concentrations and with type 1 diabetes in
Caucasians. Interestingly, their results
suggested that the risk associated with the
child’s CYP2R1 GG genotype could be
counteracted by increasing maternal VitD
intake. An inherited gene from a father
combined with male sex seems to play an
important role and mother’s VitD deficiency
during pregnancy is an additional risk
factor.
SD, standard deviation; M, mean; ASD, autism spectrum disorders; VitD, vitamin D; nmol/L, nanomoles (nmol) per litre (L); 25-OHD, a particular
form of vitamin D; 25(OH) D, a particular form of Vitamin D; CARS, the childhood autism rating scale; Ca, calcium; P, phosphorus; ALP, alkaline
phosphatase.
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Tierney et al. [2006], in a cohort of 100 individuals (78
males and 22 females) with ASD (specifically those from
families who had more than one individual diagnosed
with ASD), investigated the incidence of biochemically
diagnosed SLOS using blood samples (the typical diag-
nostic procedure). None of the samples collected had
sterol levels consistent with the full diagnosis of SLOS.
Total cholesterol levels lower than 100 mg/dL, which is
below the 5th centile for children over age 2 years,
were found in 19%. Such findings indicate that, as well
as SLOS, there may be additional disorders of sterol
metabolism or homeostasis which are related to ASD
[Tierney et al., 2006].
Tierney et al. [2001] and Sikora et al. [2006] both
found that that 50% of the children with SLOS met
autism criteria and Sikora et al. [2006] also found that
75% were on the ASD spectrum. Tierney et al. [2001]
found that, in 17 patients with SLOS, 9 met criteria for
ASD as assessed using the Autism Diagnostic Interview-
Revised [ADI-R; Lord at al., 1994], a parental interview.
In nine of the 17 patients with SLOS who started cho-
lesterol supplementation prior to the age of 5 years,
only 22% met the diagnostic criteria for ASD, compared
to 88% of those eight who did not start cholesterol sup-
plementation prior to 5 years of age. Within days of
taking cholesterol supplementation, which is before
there is a measurable change in the plasma cholesterol
or 7DHC level, a number of parents of children with
SLOS observed changes in their child’s behavior, in par-
ticular, a decrease in the number of autistic behaviors.
All these findings support the hypothesis that the
change in behavior occurs following changes in the
levels of cholesterol-derived steroid products, as opposed
to the notion that it is the level of cholesterol, which
is unable to cross the blood-brain barrier, that is
important [Lee & Tierney, 2011]. The imbalance in
cholesterol biosynthesis in individuals with SLOS leads
to impairment in myelination [e.g., Fierro, Martinez,
Harbison, & Hay, 1977; Opitz, Gilbert-Barness,
Ackerman, & Lowichik, 2002], dendrite differentiation
[e.g., Jiang et al., 2010], steroid hormone synthesis [e.g.,
Marcos, Guo, Wilson, Porter, & Shackleton, 2004;
Meljon, Watson, Wang, Shackleton, & Griffiths, 2013]
as well as impairment to the functioning of neurotrans-
mitter receptors [e.g., Waage-Baudet et al., 2003; Wassif
et al., 2001] and neurotransmitter levels [e.g., Sparks
et al., 2014]. It has been hypothesized that impairment
to these processes may be linked to the onset of symp-
toms of ASD [Bukelis, Porter, Zimmerman, & Tierney,
2007; Lecis & Segatto, 2014], a hypothesis strengthened
by studies which have indicated that a significant num-
ber of children with ASD have abnormally low levels of
plasma cholesterol [Tierney et al., 2006].
Further support for SLOS being a useful model for
ASD comes from findings which show that cholesterol
affects the oxytocin receptor [Gimpl & Fahrenholz,
2001; Gimpl, Reitz, Brauer, & Trossen, 2008; Reversi,
Rimoldi, Brambillasca, & Chini, 2006] which, when
absent in male mice, leads to marked impairments in
social recognition, obesity, and absence of body
temperature control [Nishimori et al., 2008]. Cholester-
ol is required for the high-affinity state of the oxytocin
receptor [Gimpl & Fahrenholz, 2001]. Theoretically,
cholesterol supplementation might increase oxytocin
receptor sensitivity and hence the positive effects of
oxytocin on social interaction [Aneja & Tierney, 2008].
Not only is oxytocin receptor modulated by cholesterol,
G-protein coupled receptors are also modulated by cho-
lesterol levels [for review see Alexander, Mathie, &
Peters, 2011]. Synthesis of oxytocin (OT) occurs in neu-
rons within the hypothalamus as part of a protein pre-
cursor, which, as it is transported axonally, is both
enzymatically cleaved and amidated [Gainer, Altstein,
& Whitnall, 1987]. Previous research found that social
impairments found in individuals with ASD are related
to changes in plasma OT levels [e.g., Modahl et al.,
1998]. Given that social impairments are considered to
be the primary symptoms of ASD [Fein, Joy, Green, &
Waterhouse, 1996], it was posited that this central OT
system may be impaired in individuals with ASD [Mod-
ahl, Fein, Waterhouse, & Newton, 1992; Waterhouse,
Fein, & Modahl, 1996]. Intranasal administration of OT
has been suggested by some small clinical studies to
produce social cognition improvements in individuals
with ASD [Anagnostou et al., 2012; Andari et al., 2010;
Domes et al., 2013; Guastella et al., 2010]. Improve-
ments in the symptoms and behaviors of individuals
with ASD have been reported by a number of other
small clinical studies [Green & Hollander, 2010; Hol-
lander, 2003; Hollander et al., 2007; Tachibana et al.,
2013; Theodosis et al., 2006]. Despite some modest
improvement in social stimuli attention and social
reciprocal communication, there was no significant
impact on primary outcome measures in an open label
long-term trial of OT in adolescents with ASD over a 6
month duration [Tachibana et al., 2013]. The studies to
date strongly indicate that improving function in ASD
is not as easy as simply administering a course of OT in
an intervention [Quattrocki & Friston, 2014]. See Table
5 for studies which have investigated levels of OT in
ASD. Quattrocki and Friston [2014] argue that a dys-
function in the oxytocin system, early in life, may
account for the development of ASD [Quattrocki &
Friston, 2014], at least in some cases.
Studies investigating the relationships between ASD
and cholesterol have had mixed findings. For instance,
Schengrund et al. [2012] investigated the correlation
between ASD symptoms (using the Autism Diagnostic
Interview-Revised [ADI-R]) and cholesterol in a group of
16 children with an ASD (one female and 15 males)
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and 20 typically developing control children (12
females and 8 males). All children were aged between 3
and 8 years of age. Although there was no correlation
between scores obtained using the ADI-R (total score
and subscales which measure impairment of social
interaction, limitation of communication, and presence
of repetitive and stereotypic behaviors) and cholesterol
levels, there was a significant average decrease in the
level of cholesterol within the red blood cell mem-
branes sampled from children with ASD. However,
some of the cholesterol levels were within the range
considered to be normal, supporting previous findings
[Tierney et al., 2006] suggesting that only about one in
five children with ASD exhibit a significant decreased
level of serum cholesterol levels compared to controls.
Pearson [2010] did not find a significant difference in
cholesterol levels, 7DHC, or mutations in the DHCR7
gene between individuals in a community clinic for
individuals with ASD (n542) and a control population
(n527) [Pearson, 2010]. However, mutations in the
gene DHCR24, a cholesterol synthesis gene, have been
reported to be associated with ASD [Netting, 2013].
There have been a number of other studies which have
found abnormally high total cholesterol levels and LDL
cholesterol in individuals with ASD [e.g., Dziobek,
Gold, Wolf, & Convit, 2007] and in patients with Rett
syndrome [e.g., Segatto et al., 2014]. Consistent with
this, statins (inhibitors of cholesterol biosynthesis) ame-
liorate the systemic imbalance of lipid profile, alleviate
motor symptoms, and confer increased longevity in a
mouse model of Rett syndrome [Buchovecky et al.,
2013]. Additionally, recently Blassberg et al. found
results which indicated that reduced levels of cholester-
ol impairs smoothened activation in SLOS [Blassberg,
Macrae, Briscoe, & Jacob, 2016]. [“Smoothened (SMO)”
is a protein involved in transmembrane signaling dur-
ing the process of CNS formation]. Further study is
required to elucidate this range of findings regarding
the relationship between ASD and cholesterol. There
are two lines of enquiry that look particularly promis-
ing. Specifically, studies investigating the supply of cho-
lesterol sulfate to the fetus during gestation and the
infant postnatally and studies examining myelination
in the brains of individuals with ASD and cholesterol
metabolic abnormalities.
Cholesterol Sulfate Supply to the Fetus
An insufficient supply of cholesterol sulfate to the fetus
during gestation and the infant postnatally has recently
been postulated to be the primary cause of ASD. Seneff,
Davidson, and Mascitelli [2012] hypothesized that the
key factors, in both the affected child and the mother,
are insufficient dietary sulfur and insufficient exposure
to the sun [Seneff et al., 2012]. The exact mechanisms
underlying how the mother supplies cholesterol to the
fetus are unclear and merit more investigation given
the crucial role of cholesterol in the development of
the fetal nervous system. Cholesterol has been found to
cross the blood brain barrier up to the 10th week of
life. After that the fetus is dependent on its own pro-
duction. Thus, mothers with high cholesterol levels can
give birth to children with low cholesterol levels. Sen-
eff, Davidson, Lauritzen, Samsel, and Wainwright
[2015] have published a number of articles with
hypotheses as to the role of cholesterol sulfate and sul-
fur such as a hypothesis for atherosclerosis as a choles-
terol sulfate deficiency syndrome.
In sum, research to date provides some support for
the hypothesis that defective cholesterol and related
compound homeostasis may be responsible for the
onset of ASD in some children, suggesting that investi-
gating whether cholesterol may be a useful biomarker
for certain ASD subtypes is worthwhile [Woods et al.,
2013].
Myelination in the Brains of Individuals with ASD
and Cholesterol Metabolic Abnormalities
The largest pool of cholesterol exists in myelin mem-
branes and disorders that interfere with sterol and
cholesterol synthesis cause hypomyelination [Saher &
Stumpf, 2015]. In addition, myelination abnormalities
have been detected in patients with Fragile X syndrome
suggesting that dysfunctions of myelination at the cel-
lular and/or circuitry level may play a role in the patho-
logical manifestations of this syndrome [Kalinowska,
Castillo, & Francesconi, 2015]. Also, in autism in gener-
al, abnormalities in white matter integrity and in func-
tional connectivity have been demonstrated [Kana,
Libero, Hu, Deshpande, & Colburn, 2014; Travers et al.,
2012] supporting the interdependence of sterol/lipid
metabolism and autism.
Future Directions
This hypothesis paper highlights the need for future
studies to investigate the levels of multiple steroid hor-
mones in individuals with ASD – especially cholesterol
and VitD. To further explore the role of cholesterol in
children with ASD, it might be possible to analyse the
neonatally taken Guthrie spots with regard to relevant
compounds [Starck & L€ovgren, 2000], based on access
to representative large clinical samples of children with
ASD and controls. Lastly, SLOS patients can, theoretical-
ly, have adequate levels of VitD from either sun expo-
sure or supplementation because the pathways for VitD
and cholesterol synthesis are completely separated.
Therefore, low levels of cholesterol do not imply low
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Table 5. Studies Investigating Level of Oxytocin in Autism Spectrum Disorder
Oxytocin receptor modulation and autism spectrum disorder
Authors Sample study aims Main findings
Al-Ayadhi [2005] Seventy-seven children with ASD
participated in the study, 71
males (92.2%) and 6 females
(7.8%).
Seventy-seven healthy age and sex
matched controls
To investigate plasma levels of oxytocin
and vasopressin in children with ASD.
Also, to correlate plasma levels of
those neuropeptides to the degree of
ASD and age of the affected child.
Another aim was to explore the role
of Pitocin induction in the genesis of
ASD.
Oxytocin (OT) and vasopressin levels
were also found to be lower in 77
boys with ASD from central Saudi
Arabia compared to the boys without
ASD.
No significant correlation between the
severity of ASD, or the age of the
affected child and plasma levels of
oxytocin or vasopressin was found. A
greater incidence of Pitocin-induced
labor among the group with ASD
compared to the controls.
Andari
et al. [2010]
13 patients with HF-ASD and 13
matched healthy participants.
To investigate the behavioral effects of
oxytocin in 13 participants with ASD.
Study found marked decreased levels of
oxytocin (OT) in 13 high functioning
autism patients with ASD compared
to controls.
Crespi and
Hurd [2015]
Questionnaire data and DNA samples
from Caucasian undergraduate
psychology students (175 males
and 309 females) at the
University of Alberta and Simon
Fraser University.
Study aimed to investigate associations
of genetically based indicators of
serum oxytocin, and serum
testosterone, with measures of
autism-spectrum and schizophrenia-
spectrum cognition in healthy
individuals.
Low genetic index of testosterone, a
high genetic index of oxytocin (OT),
and/or a low ratio of testosterone to
OT indices were positively correlated
with high imagination (as measured
by the Autism Quotient) and high
positive and total schizotypy (as
measured by the Schizotypal
Personality Questionnaire). In the
Autism Spectrum Quotient, the
Imagination subscale measures areas
of social imagination which overlap
with mentalistic cognitions such as
theory of mind, which previous
studies have identified as being
association with levels of OT.
Green et al. [2001] 28 males (976 20 months; range,
70–139 months), diagnosed with
DSM-IV autistic disorder through
observation and semistructured
interview.
31 age-matched nonpsychiatric con-
trols (1066 22 months; range,
74–140 months).
To investigate whether there were
changes in OT peptide forms in
children with ASD compared to
children without ASD.
Findings support the role of OT in ASD.
Findings revealed that plasma OT is
reduced in children with ASD and
also has abnormal associations with
social abilities. There are numerous
pathways for this association such as
alterations in either the brain OT
axis, the peptide receptors, and/or in
peptide synthesis and processing.
Lakatosova
et al. [2013]
8 children with ASD. To investigate the potential
correlations between both peripheral
levels of oxytocin (OT) and
testosterone with ASD symptomology.
Findings revealed a positive correlation
between OT levels and the
Adaptation to change category of
The Childhood Autism Rating ScaleTM,
Second Edition (CARS-2) and
maladapative behavior scores as
measured on The Vineland Adaptive
Behavior Scales, Second Edition
(Vineland-II). There were no
significant correlations between
levels of testosterone and behavioral
parameters. Elevated levels of OT
were associated with more severe
scores of adaptive behavior in ASD
patients. It appears that, in
individuals with ASD, OT recruits a
different mechanism to modulate
social behavior compared to the
general population.
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Table 5. Continued
Oxytocin receptor modulation and autism spectrum disorder
Authors Sample study aims Main findings
Miller
et al. [2013]
75 preadolescent and adolescent
girls and boys ages 8–18: 40 with
high-functioning ASD (19 girls,
21 boys) and 35 typically devel-
oping children (16 girls, 19
boys).
To investigate:
(1) plasma levels of oxytocin (OT) and
arginine vasopressin (AVP) in TYP
girls and boys and those with ASD
(2) to relate these levels of OT and AVP
to measures of social, language,
repetitive behavior, & internalizing
symptoms
Study did not find any differences
between the levels of OT and
vasopressin in their sample of 75
patients with ASD compared to age-
matched controls in a United States
population.
Higher OT values were associated with
greater anxiety in all girls. Higher OT
values were also found to be
associated with better pragmatic
language in both boys and girls. AVP
levels were positively associated with
restricted & repetitive behaviors in
girls with ASD. AVP levels were
negatively (non-significantly)
associated with these behaviors in
boys with ASD.
Modahl
et al. [1998]
29 children with ASD and 30 age-
matched typically developing
children, all prepubertal.
To investigate whether children with
ASD have abnormalities in OT
compared to controls using
radioimmunoassay for levels of OT.
Children with ASD were found to have
plasma OT levels which were
significantly lower compared to those
in the typically developing group.
Moreover, in the typically developing
group, OT was found to increase with
age, an increase which was not
exhibited in the individuals with
ASD. Higher scores on social and
developmental measures were
associated with elevated OT for the
children without ASD. However, in
the children with ASD, lower scores
on social and developmental
measures were associated with
elevated OT. In the children with
ASD who were identified as being
‘aloof’ this association was even more
marked.
Taurines
et al. [2014]
19 children and adolescents with
ASD, all male (mean age 10.7,
SD5 3.8 years compared to two
other groups, 17 healthy male
children (mean age 13.6,
SD5 2.1 years) and 19 male
children with attention deficit
hyperactivity disorder (ADHD)
(mean age 10.4, SD5 1.9 years).
To investigate the changes in
concentration levels of peripheral OT
(OT plasma concentrations) using a
validated radioimmunoassay.
Findings revealed a correlation between
OT plasma concentrations with
number of ASD symptom (as
measured using the Autism
Diagnostic Observation Schedule) in
children with ASD.
Weisman
et al. [2015]
All singleton live births in Denmark
between 2000 and 2009
(n5 557,040) with a follow-up
through 2012. In this cohort,
2,110 children were later diag-
nosed with ASD.
To investigate oxytocin-augmented
labor and risk for ASD.
Findings showed that augmentation of
labor with oxytocin (OT) was only
modestly associated with an
increased risk for ASD in males only.
In the group of males exposed to OT
augmentation, 560 were later
diagnosed with ASD (incidence rate
103.2 per 100,000 person-years). In
the males not exposed to OT
augmentation, 1,177 fulfilled the
criteria for an ASD (incidence rate
81.4 per 100,000 person-years).
SD, standard deviation; M, mean; ASD, autism spectrum disorders; OT, oxytocin; HF-ASD, high-functioning autism spectrum disorder; DNA, deoxy-
ribonucleic acid; DSM-IV, diagnostic and statistical manual of mental disorders, 4th edition; CARS-2, the childhood autism rating scaleTM, second edi-
tion; Vineland-II, the vineland adaptive behavior scales, second edition; AVP, arginine vasopressin.
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VitD. Future study could investigate VitD levels in indi-
viduals with SLOS.
The study carried out by Baron-Cohen et al. [2015],
reviewed above in the “Testosterone in Autism Spec-
trum Disorders” subsection, was the first direct evidence
of elevated fetal steroidogenic activity in ASD. Their
findings are consistent with the fetal steroid theory in
providing some understanding as to some features of
early epigenetic risk for ASD and/or other sex-biased
neurodevelopmental conditions which occur during
fetal brain development. They argued that these elevat-
ed levels of fetal steroidogenic activity may be
“important as epigenetic fetal programming mecha-
nisms and may interact with other important patho-
physiological factors in autism” [Baron-Cohen et al.,
2015, p. 370] and highlighted the need for future
research to explore the potential underlying mecha-
nisms, as well as the role of sex steroids, in the etiology
of ASD [Baron-Cohen et al., 2015]. We concur, given
the findings across the studies reported in the present
review, that there is a significant important need to
investigate this area of research in more detail. More-
over, Baron-Cohen et al. [2015] also point out a poten-
tial limitation with their study in that they did not test
the source of elevated steroidogenic activity in the fetal
development of ASD. As a result, they argue that there
is a requirement for more research in order to under-
stand the way in which a variety of sources (including,
the fetus, mother, placenta, or other environmental fac-
tors) might contribute to the observed elevated concen-
tration levels of D4 sex steroids (progesterone, 17a-
hydroxy-progesterone, androstenedione, and testoster-
one) and cortisol that they found in their study. Fur-
ther, Baron-Cohen et al. argued that it is important for
future research to investigate if “such elevations are spe-
cific to ASD or are shared by other neurodevelopmental
conditions with skewed sex ratios, and to test whether
similar elevations exist in females with autism” [Baron-
Cohen et al., 2015, p. 379]. Given the well-established
co-morbidity between ASD and other sex-biased condi-
tions including ADHD, conduct disorder (CD) and anxi-
ety disorder as well as the relationships between these
sex-biased conditions and levels of prenatal stress [e.g.,
O’Connor, Heron, Golding, & Glover, 2003; Simonoff
et al., 2008], the elevated levels of fetal steroid activity
may not be unique to ASD [Baron-Cohen et al., 2015].
Additionally, the study carried out by Kosidou et al.
[2016] (and reviewed in the same subsection as the
study by Baron-Cohen et al. [2015] discussed above)
found that children of mothers with PCOS are at
increased risk of developing ASD. The risk was the same
irrespective of sex. These findings are consistent with
the theory that in both males and females, early life
androgen exposure may play a crucial role in the devel-
opment of ASD. Therefore, research investigating the
mechanisms involving sex steroids in the etiology of
ASD is needed [Kosidou et al., 2016]. Although there
are numerous studies suggesting that there is an inter-
action between genetic and environmental factors in
the etiology of ASD, our relatively sparse knowledge
and understanding of the underlying mechanisms
presents potential barriers to informing the develop-
ment of appropriate, timely and effective ways of iden-
tifying and preventing ASD [Kosidou et al., 2016].
Recently, Whitehouse [2016] argued that “future
research must first understand how the prenatal hor-
mone environment relates to individual behavioral
dimensions, and then incorporate this knowledge into
the investigation of links with the more aetiologically
and phenotypically complex profile of ASD” [White-
house, 2016, p. 1,464].
We would suggest that in new studies in the field of
neurodevelopmental disorders and possible links with
sterol abnormalities, all of the following (and possibly
more) should be included in the “work-up kit” in all
individuals recruited for study: serum levels of choles-
terol, 7- and 8 dehydrocholesterol, 25-OH vitamin D,
testosterone, estrogen, cortisol (although diurnal varia-
tion may be a particular aspect to consider here) and 7-
dehydrocholesterol reductase. In collaboration with
chemists and geneticists a variety of enzyme and gene
tests may then be added to the protocol depending on
specific research questions in any particular study.
Conclusions
The “extreme male brain” theory of ASD [Baron-Cohen,
2002] has generated hypotheses about the role of elevat-
ed fetal sex steroids such as testosterone in the develop-
ment of ASD. However, it does not discuss the
contribution of other factors such as sex chromosome
effects or the involvement of other steroid hormones
proximal to testosterone in biosynthesis pathways
including: VitD, estradiol, cortisol, and progesterone. So,
although the majority of research to date has focused on
fetal testosterone and ASD, it appears that the actions of
testosterone as well as other precursor steroid hormones
within the same biosynthesis pathway may all contribute
to fetal development in ASD [Baron-Cohen et al., 2015].
In this hypothesis paper, we reviewed studies which
linked some of the steroid hormones, specifically VitD,
with levels of cholesterol. The steroid hormones we
reviewed (testosterone; estrogens; cortisol, and VitD) all
have studies which indicate their link with ASD. There-
fore, it is possible that there may exist a cholesterol-
steroid hormone pathway underlying the development
of ASD.
In sum, this review indicates that there may be links
between “steroid metabolism” and findings of steroid
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abnormalities of various kinds (cortisol, testosterone,
estrogens, vitamin D) in ASD. Further research investigat-
ing these potential links is warranted to further our under-
standing of the biological mechanisms underlying ASD.
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